FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2052246131> ?p ?o ?g. }

• W2052246131 endingPage "2515" @default.
• W2052246131 startingPage "2507" @default.
• W2052246131 abstract "Lipoatrophy is prevalent on thymidine nucleoside reverse transcriptase inhibitors (tNRTIs). A pilot trial showed that uridine (NucleomaxX) increased limb fat.A5229 was a multicenter trial in which HIV-infected individuals with lipoatrophy on tNRTI regimens were randomized to NucleomaxX or placebo. Primary endpoint was change in limb fat from baseline to week 48. The study was powered to detect 400-g difference between arms at week 48. A stratified Wilcoxon rank-sum test was used to assess between-arm differences.The 165 participants were 91% men, 62% white; median age 49 years, CD4 cell count 506 cells/μl, and limb fat 3037 g; 81% had HIV-1 RNA 50 copies/ml or less; 76% were on zidovudine (ZDV). Baseline characteristics were similar between groups. Only 59% completed 48 weeks of treatment; however, only three participants (one on uridine) discontinued due to toxicity (diarrhea). In intent to treat, there was no difference for changes in limb fat between treatments at week 24 or week 48. On as-treated analysis, uridine resulted in an increase in %limb fat vs. placebo (3.4 vs. -0.8%, P = 0.01) at week 24 but not at week 48 (1.8 vs. 3.8%, P = 0.93). Similar results were seen when limiting the analysis to patients with at least 80% adherence. The results were not related to severity of lipoatrophy or type of tNRTI. No changes were found in facial anthropometrics, fasting lipids, trunk fat, CD4 cell count, or HIV RNA.We found a modest transient improvement in limb fat after 24 weeks of uridine. The lack of sustained efficacy at week 48 was not due to changes in adherence or reduction in sample size. Uridine was well tolerated and did not impair virologic control." @default.
• W2052246131 created "2016-06-24" @default.
• W2052246131 creator A5000167800 @default.
• W2052246131 creator A5008396092 @default.
• W2052246131 creator A5010836135 @default.
• W2052246131 creator A5015076603 @default.
• W2052246131 creator A5015745991 @default.
• W2052246131 creator A5040451147 @default.
• W2052246131 creator A5048457292 @default.
• W2052246131 creator A5052156100 @default.
• W2052246131 creator A5084353681 @default.
• W2052246131 creator A5088973456 @default.
• W2052246131 date "2010-10-23" @default.
• W2052246131 modified "2023-10-13" @default.
• W2052246131 title "Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229" @default.
• W2052246131 cites W1971987445 @default.
• W2052246131 cites W198882071 @default.
• W2052246131 cites W1997900349 @default.
• W2052246131 cites W2013711685 @default.
• W2052246131 cites W2016940850 @default.
• W2052246131 cites W2026265351 @default.
• W2052246131 cites W2027879459 @default.
• W2052246131 cites W2050999867 @default.
• W2052246131 cites W2082869272 @default.
• W2052246131 cites W2161057792 @default.
• W2052246131 cites W2165003108 @default.
• W2052246131 cites W2321741507 @default.
• W2052246131 cites W2403594926 @default.
• W2052246131 doi "https://doi.org/10.1097/qad.0b013e32833ea9bc" @default.
• W2052246131 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2956768" @default.
• W2052246131 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20827170" @default.
• W2052246131 hasPublicationYear "2010" @default.
• W2052246131 type Work @default.
• W2052246131 sameAs 2052246131 @default.
• W2052246131 citedByCount "23" @default.
• W2052246131 countsByYear W20522461312012 @default.
• W2052246131 countsByYear W20522461312013 @default.
• W2052246131 countsByYear W20522461312014 @default.
• W2052246131 countsByYear W20522461312015 @default.
• W2052246131 countsByYear W20522461312016 @default.
• W2052246131 countsByYear W20522461312019 @default.
• W2052246131 countsByYear W20522461312021 @default.
• W2052246131 crossrefType "journal-article" @default.
• W2052246131 hasAuthorship W2052246131A5000167800 @default.
• W2052246131 hasAuthorship W2052246131A5008396092 @default.
• W2052246131 hasAuthorship W2052246131A5010836135 @default.
• W2052246131 hasAuthorship W2052246131A5015076603 @default.
• W2052246131 hasAuthorship W2052246131A5015745991 @default.
• W2052246131 hasAuthorship W2052246131A5040451147 @default.
• W2052246131 hasAuthorship W2052246131A5048457292 @default.
• W2052246131 hasAuthorship W2052246131A5052156100 @default.
• W2052246131 hasAuthorship W2052246131A5084353681 @default.
• W2052246131 hasAuthorship W2052246131A5088973456 @default.
• W2052246131 hasBestOaLocation W20522461311 @default.
• W2052246131 hasConcept C104317684 @default.
• W2052246131 hasConcept C126322002 @default.
• W2052246131 hasConcept C134018914 @default.
• W2052246131 hasConcept C141071460 @default.
• W2052246131 hasConcept C142462285 @default.
• W2052246131 hasConcept C142724271 @default.
• W2052246131 hasConcept C203014093 @default.
• W2052246131 hasConcept C204787440 @default.
• W2052246131 hasConcept C27081682 @default.
• W2052246131 hasConcept C2776452011 @default.
• W2052246131 hasConcept C2777351918 @default.
• W2052246131 hasConcept C2779546735 @default.
• W2052246131 hasConcept C2780216070 @default.
• W2052246131 hasConcept C2780727368 @default.
• W2052246131 hasConcept C2781259782 @default.
• W2052246131 hasConcept C2993143319 @default.
• W2052246131 hasConcept C3013748606 @default.
• W2052246131 hasConcept C55493867 @default.
• W2052246131 hasConcept C67705224 @default.
• W2052246131 hasConcept C71924100 @default.
• W2052246131 hasConcept C86803240 @default.
• W2052246131 hasConcept C90924648 @default.
• W2052246131 hasConceptScore W2052246131C104317684 @default.
• W2052246131 hasConceptScore W2052246131C126322002 @default.
• W2052246131 hasConceptScore W2052246131C134018914 @default.
• W2052246131 hasConceptScore W2052246131C141071460 @default.
• W2052246131 hasConceptScore W2052246131C142462285 @default.
• W2052246131 hasConceptScore W2052246131C142724271 @default.
• W2052246131 hasConceptScore W2052246131C203014093 @default.
• W2052246131 hasConceptScore W2052246131C204787440 @default.
• W2052246131 hasConceptScore W2052246131C27081682 @default.
• W2052246131 hasConceptScore W2052246131C2776452011 @default.
• W2052246131 hasConceptScore W2052246131C2777351918 @default.
• W2052246131 hasConceptScore W2052246131C2779546735 @default.
• W2052246131 hasConceptScore W2052246131C2780216070 @default.
• W2052246131 hasConceptScore W2052246131C2780727368 @default.
• W2052246131 hasConceptScore W2052246131C2781259782 @default.
• W2052246131 hasConceptScore W2052246131C2993143319 @default.
• W2052246131 hasConceptScore W2052246131C3013748606 @default.
• W2052246131 hasConceptScore W2052246131C55493867 @default.
• W2052246131 hasConceptScore W2052246131C67705224 @default.
• W2052246131 hasConceptScore W2052246131C71924100 @default.
• W2052246131 hasConceptScore W2052246131C86803240 @default.
• W2052246131 hasConceptScore W2052246131C90924648 @default.

• next